Shenzhen hosts the 2nd AGP&DTx Summit Forum: Advancing Digital Therapy in Diabetes Management

Saturday, July 13, 2024

On July 5, the second Ambulatory Glucose Profiling (AGP) and Digital Therapeutics (DTx), led by the National Innovation Center for Advanced Medical Devices, sponsored by China AGP and DTx Digital Therapeutics R&D Center (“R&D Center”), co-sponsored by Shenzhen SIBIONICS Technology Co., Ltd. (“SIBIONICS”), was held in Shenzhen, China . Domestic and foreign healthcare experts gathered at the Summit Forum to explore the application of AGP in diabetes precision diagnosis and treatment and digital therapeutics during the decision-making process of clinical practice around the world.

The Summit Forum , hosted by Professor Ji Linong , initiator of China AGP&DTx R&D Center and clinical professor of Peking University People's Hospital, was attended by top endocrinology experts from Slovenia, Australia , Saudi Arabia, Serbia, Turkey, Algeria and other countries. The experts explored critical topics including AGP consensus, Chinese diabetes patient database, artificial pancreas system and digital health management. They also discussed the latest developments in diabetes management technology and its practical applications in clinical practice.

At the conference, Professor Andrej Janež, Head of the Department of Endocrinology at the University of Ljubljana Medical Centre in Slovenia, highlighted China 's advances in the clinical practice of AGP. He commented: "They have developed an AGP training programme and are moving into the area of ​​research and use of AI to improve diagnosis and guide treatment decisions, leading to better diabetes care and facilitating AGP applications."

To integrate global resources and drive innovation in diabetes diagnosis and treatment, the AGP&DTx International R&D Consortium was founded in this forum. This initiative aims to standardize AGP clinical applications globally and provide a platform for international collaboration and knowledge sharing to elevate diabetes diagnosis and treatment worldwide.

About SIBIONICS

Founded in 2015, SIBIONICS is committed to the R&D and industrialization of implantable medical devices. By fusing cutting-edge CGM technology with diabetes patient-centric designs, SIBIONICS strives to push the boundaries of what is possible in personalized diabetes management solutions. With over 1,000,000 users worldwide, SIBIONICS is now a model of reliability and innovation in diabetes management.





Source: prnewswire.com